Compare LMNR & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LMNR | PRLD |
|---|---|---|
| Founded | 1893 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.6M | 207.5M |
| IPO Year | 2005 | 2020 |
| Metric | LMNR | PRLD |
|---|---|---|
| Price | $13.25 | $3.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $20.00 | $4.67 |
| AVG Volume (30 Days) | 52.5K | ★ 316.0K |
| Earning Date | 06-15-2026 | 06-17-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,723,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | $14.86 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $12.20 | $0.61 |
| 52 Week High | $18.40 | $4.19 |
| Indicator | LMNR | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 54.67 |
| Support Level | $12.69 | $1.02 |
| Resistance Level | $15.13 | $4.10 |
| Average True Range (ATR) | 0.42 | 0.33 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 27.20 | 41.78 |
Limoneira Co is predominantly an agribusiness company. Its current operations consist of fruit production and marketing, rental operations, real estate, and capital investment activities. The company has three business divisions; agribusiness, rental operations, and real estate development. The agribusiness division which accounts for a majority of the firm's revenue represents its core operations of farming, harvesting, lemon packing, and lemon sales operations. The company's reportable operating segments are fresh lemons, lemon packing, avocados, and other agribusiness, which predominantly includes oranges, specialty citrus, other crops, and farm management services. A majority of its revenue is derived from the Fresh Lemons segment.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.